These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22266126)

  • 21. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
    Gottlieb A; Menter A; Mendelsohn A; Shen YK; Li S; Guzzo C; Fretzin S; Kunynetz R; Kavanaugh A
    Lancet; 2009 Feb; 373(9664):633-40. PubMed ID: 19217154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
    Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
    Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of ustekinumab for the treatment of psoriatic arthritis.
    López-Ferrer A; Laiz A; Puig L
    Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
    Fragoulis GE; Siebert S; McInnes IB
    Annu Rev Med; 2016; 67():337-53. PubMed ID: 26565676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
    Gandhi M; Alwawi E; Gordon KB
    Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
    Deepak P; Sandborn WJ
    Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis.
    Hou M; Xing H; Cai Y; Wang X; Xie Z; Zhang Q; Ma Y; Chen J
    Eur J Dermatol; 2019 Jun; 29(3):302-314. PubMed ID: 31389789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological treatment of psoriasis and psoriatic arthritis].
    Kragballe K; Deleuran B
    Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS; Horn EJ; Cather JC
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
    Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
    MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
    Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
    J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-12, interleukin-23, and psoriasis: current prospects.
    Torti DC; Feldman SR
    J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.
    Gedebjerg A; Johansen C; Kragballe K; Iversen L
    Acta Derm Venereol; 2013 Mar; 93(2):150-5. PubMed ID: 22930279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
    Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
    Ann N Y Acad Sci; 2012 Aug; 1263():1-12. PubMed ID: 22823582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
    Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.